Optogenetic Therapy Shows Early Signs of Improving Vision in Inherited Blindness
Seven of 10 participants improved light sensitivity, and four could find doorways or follow lines with custom goggles, researchers reported.
- Researchers published a study on Wednesday in The New England Journal demonstrating that optogenetic therapy can improve light sensitivity in patients with Retinitis, a degenerative condition affecting more than 1.5 million people worldwide.
- Because Retinitis is driven by over 100 possible genetic mutations, traditional gene-specific treatments prove difficult; this approach bypasses those limitations by introducing light-sensitive proteins directly into retinal cells regardless of genetic cause.
- In a phase 1 trial involving 10 participants, researchers paired a viral injection with specialized goggles that convert visual information into amber light pulses. Four participants could successfully detect objects like doorways or follow a line.
- Seven participants showed improved light sensitivity, with six reaching "clinically meaningful" gains. Although 34 adverse events were recorded—mostly temporary inflammation—the results suggest the therapy is safe and capable of restoring some visual activity.
- On October 5, the 2026 Nobel Prize in Physiology or Medicine recognized pioneering optogenetics work, as Professor José-Alain Sahel noted that this trial provides a "proof of concept" encouraging future optimization efforts.
18 Articles
18 Articles
An international team of researchers has conducted a successful clinical trial of optogenetic therapy in blind patients with advanced retinitis pigmentosa. The procedure, which combines gene therapy and special glasses, was found to be safe, improved light sensitivity in the majority of patients tested, and allowed for partial restoration of object perception.
Signs of restoration of vision in 10 people (ANSA)
Scientists from France, the United States and Switzerland partially restored their eyesight to seven volunteers using experimental therapy based on Nobel optogenetic technologies, reported at Pittsburgh University. The International Group of Molecular Biologists partially restored their eyesight to seven patients with retina dystrophia using optogenetic technologies to transfer TASS. Ten fully blinded volunteers participated in the experiment, w…
A clinical trial, conducted in ten people who are not sighted in France, the United States and the United Kingdom, suggests the interest in restoring a form of vision in a treatment that involves injecting a viral vector with genetic construction into the eye.
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
